Cart
sales@molnova.com
GSK 635416A
CAS No. 944729-29-7
GSK 635416A( GSK635416A )
Catalog No. M16767 CAS No. 944729-29-7
GSK 635416A is a novel ATM inhibitor with highly selective radiosensitizing activity, inhibits radiation induced phosphorylation of ATM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameGSK 635416A
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK 635416A is a novel ATM inhibitor with highly selective radiosensitizing activity, inhibits radiation induced phosphorylation of ATM.
-
DescriptionGSK 635416A is a novel ATM inhibitor with highly selective radiosensitizing activity, inhibits radiation induced phosphorylation of ATM; exhibits virtually no cytotoxicity in the absence of radiation and in normal fibroblast cells, enhances IR effect in radiosensitizing HNSCC cell lines but not in normal fibroblast BJ-ET cells in combined with olaparib.
-
In Vitro——
-
In Vivo——
-
SynonymsGSK635416A
-
PathwayCell Cycle/DNA Damage
-
TargetATM/ATR
-
RecptorATM/ATR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number944729-29-7
-
Formula Weight453.532
-
Molecular FormulaC24H24FN3O3S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name2-amino-5-(4-fluorophenyl)-N-methyl-3-(4-pyrrolidin-1-ylsulfonylphenyl)benzamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Dohmen AJC, et al. Oncotarget. 2017 May 19;8(43):73925-73937.
molnova catalog
related products
-
Ro 90-7501
Ro 90-7501 is an amyloid β42 (Aβ42) protofibrillar and TPR-dependent PP5 inhibitor, a novel radiosensitizer for cervical cancer cells, which inhibits ATM phosphorylation, promotes apoptosis, and induces cell-cycle arrest.
-
AZD1390
AZD1390 (AZD-1390) is a novel potent, selective, orally available and CNS penetrant ATM inhibitor with IC50 of 0.78 nM.Brain Cancer,Phase 1 Clinical
-
AZD-0156
AZD-0156 (AZD0156, AZD 0156)?is a potent, highly selective and orally bioavailable ATM inhibitor; exhibits antitumoral activity, both reducing tumor burden and preventing tumors from growing in an immunocompetent allograft mouse model of AML.Solid Tumors,Phase 1 Clinical
